Focus::CLL? is the only CLIA-validated and NYS-approved NGS panel for CLL that offers information for patient risk stratification, disease management, and treatment selection Focus::CLL? addresses a significant market of over 120,000 patients in ... Pharmacy Choice, 7 hours ago
1 images for "unique pharmaceutical laboratories"
WALTHAM, Mass.--( BUSINESS WIRE )-- Morphic Therapeutic , a biotechnology company developing a new generation of oral integrin drugs, announced today that it has completed a $51.5 million Series A financing to advance multiple programs into the ...Citybizlist, 38 minutes ago
AbbVie's HUMIRA® (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis
/PRNewswire/ --AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for the treatment of non-infectious intermediate, posterior and panuveitis.Barchart, 1 hour ago
Ajay Jagtiani Brings Experienced Patent Prosecution Team to Support I-270 Businesses The full-service mid-Atlantic law firm of Miles & Stockbridge today announced that respected intellectual property lawyer Ajay A. Jagtiani has joined the firm as ...Citybizlist, 2 hours ago
Droplet Digital PCRBased Assay Quickly and Cost-Effectively Assesses Genome-Editing Events Hercules, CA — June 28, 2016 — Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other ...BioSpace, 4 hours ago
Cannabis Science Guidance; Corporate Headquarters Relocated to California as it Negotiates for a Los Angeles, California Laboratory/Medical Treatment Center
CBIS Sets the Stage for High-Growth Amidst DEA Historical National Industry Changes for Critical Ailment Treatments & Historic California Voting in November LOS ANGELES, CA--(Marketwired - Jun 30, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), ...Financial Buzz, 5 hours ago
* † , Hiroaki Yamaguchi ‡ , Motoi Kikusato § , Osamu Hashizume ‖ , Satoru Nagatoishi ¶ , Akihiro Matsuo * , Takeya Sato ** , Tai Kudo †† , Tetsuro Matsuhashi ‡‡ , Kazutaka Murayama §§ , Yuki Ohba * , Shun Watanabe * , ...Journal American Society of Nephrology, 6 hours ago
ABSTRACT Drugs for serious fungal and microbial infections currently require intravenous administration at doses that are associated with significant toxicity. Orally administered, encochleated formulations of broad-spectrum fungicidal and ...Drug Development & Delivery, 7 hours ago
Home » Health » / no comments IMAGE: Ian D. Krantz, M.D., is the director of the Individualized Medical Genetics Center at The Children's Hospital of Philadelphia. view more Credit: The Children's Hospital of Philadelphia A quiet ...HealthMediciNet.com, 7 hours ago
on your WebpageAdd Widget >Get your members hooked!